Customers who bought this item also bought

• UK Electronic Cigarettes Market 2011-2015
• Future Horizons in the UK Tumor Marker Testing Market: Supplier Shares and Sales Forecasts for 40 Cancer Assays by Market Segment
• The UK Health and Wellness Industry Outlook to 2017 - Robust Growth in Fitness and Nutraceutical Segment
• United Kingdom Diagnostic Imaging Market Outlook to 2017 - Ultrasound Systems, MRI Systems, Computed Tomography Systems, Nuclear Imaging Equipment, X-Ray Systems, Mammography Equipment and Others
• United Kingdom In Vitro Diagnostics Market Outlook to 2017- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture
• The UK Molecular Diagnostics and NAT Market: Sales Forecasts and Key Supplier Shares (DataPack)
• United Kingdom Ophthalmic Devices Market Outlook to 2017 - Vision Care, Ophthalmic Diagnostic Equipment, Cataract, Refractive, Vitreo Retinal and Glaucoma Surgery Devices
• Western European Insulin Delivery Devices Market
• United Kingdom In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture
• UK Blood Pressure Monitors Forecasts to 2018

Type 2 DM management with combination therapy. Edition No. 1

VDM Publishing House, January 2010, Pages: 64

Abstract Introduction A meta analysis was conducted to evaluate the efficacy and safety profile of, insulin with oral hypoglycaemic agents, versus insulin monotherapy, in type2 diabetes patient's management. Search strategy The following databases were searched: The Cochrane Library, Medline, Embase, Pub Med, High wire Press and Science Direct. Selection criteria Randomised controlled trials (RCTs of any design) with a minimum follow-up period two months, Over 18 year old men and women were recruited with type 2 diabetes mellitus as defined by the world health Organization (Alberti 1998), participants were not controlled on their current oral antidiabetic agents, mean that Hba1c > 7% or a fasting plasma glucose >7 mmol/l. Conclusion Insulin with oral hypoglycaemic agents gives good glycaemic control as well as prevents weight gain and less hypoglycaemia than insulin monotherapy.

Khandker Parvez, Ahmad.
Dr.Khandker Parvez Ahmad.Born in Pabna district,Bera thana,In Bangladesh.He completed his secondary and higher secondary at Pabna Zilla school and Notre dame college. Than got Bachelor of medicine and sergery (MBBS)BD. Than Completed MSc in Diabetes At Queen Margaret University,Edinburgh,UK.